Cargando…

Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database

BACKGROUND: Major improvements in the management of rheumatoid arthritis (RA) have made clinical remission an achievable and desirable goal but, despite the relevance gained by a profound disease suppression, many patients with RA still miss clinical remission due to several factors influencing dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanetti, Anna, Zambon, Antonella, Scirè, Carlo A., Bugatti, Serena, Montecucco, Carlomaurizio, Sakellariou, Garifallia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552453/ https://www.ncbi.nlm.nih.gov/pubmed/37807981 http://dx.doi.org/10.1177/1759720X231194179

Ejemplares similares

In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2021)

Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases
por: Sakellariou, Garifallia, et al.
Publicado: (2022)

Performance of the 2010 Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review and a Meta-Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2013)

Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2021)

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study
por: Montecucco, Carlomaurizio, et al.
Publicado: (2012)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis
por: Wennink, Roos A. W., et al.
Publicado: (2022)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
por: Nozaki, Yuji
Publicado: (2021)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
por: Bugatti, Serena, et al.
Publicado: (2012)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
por: Xie, Wenhui, et al.
Publicado: (2023)

Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China
por: Sun, Jiaying, et al.
Publicado: (2020)

Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis
por: Crepaldi, Gloria, et al.
Publicado: (2016)

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
por: Iwamoto, Naoki, et al.
Publicado: (2022)

Electra /
por: Eurípides
Publicado: (1989)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
por: Genovese, Mark C., et al.
Publicado: (2020)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
por: Sun, Zhijian, et al.
Publicado: (2022)

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
por: Mueller, Ruediger B., et al.
Publicado: (2019)

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
por: Väänänen, Tuija, et al.
Publicado: (2017)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
por: İNANÇ, Güzide Nevsun, et al.
Publicado: (2023)

Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Sakellariou, Garifallia, et al.
Publicado: (2022)

Retorno de Electra
por: Ochoa, Enriqueta, 1928-
Publicado: (1978)

Retorno de Electra
por: Ochoa, Enriqueta
Publicado: (1986)

Retorno de Electra /
por: Ochoa, Enriqueta, 1928-
Publicado: (1978)

Retorno de Electra
por: Ochoa, Enriqueta, 1928-
Publicado: (1978)

Mourning becomes electra : a trilogy.
por: O'Neill, Eugene Gladstone, 1888-
Publicado: (1931)

Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective
por: Bugatti, Serena, et al.
Publicado: (2012)

Rheumatoid arthritis treatment: the earlier the better to prevent joint damage
por: Monti, Sara, et al.
Publicado: (2015)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
por: Bugatti, Serena, et al.
Publicado: (2018)

ELECTRA letters of intent and addendum
por: Cashmore, Roger J, et al.
Publicado: (1982)

Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?
por: Bugatti, Serena, et al.
Publicado: (2018)

Memorandum: a hypothetical staging of ELECTRA
por: CERN. Geneva. LEP Experiments Committee
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_415no824d9cnjqcpbubt15ac6a